Drug discovery and development – Page 7
-
BusinessWeight-loss drug shortages prompt copycats and counterfeits
Novo Nordisk and Eli Lilly have struggled to meet huge demand for new hormone mimic obesity treatments
-
ResearchUnderwater device reveals marine chemical diversity
I-Smel device probes metabolites produced by Mediterranean sponges
-
FeatureBattling long Covid with drugs
The challenge of finding drugs for a poorly understood disease with many symptoms is clear. Clare Sansom looks at the work going on to help the people suffering in its shadow
-
OpinionLetters: October 2023
Readers discuss antibiotic challenges, muse about micrographs and remember Philip Eaton
-
NewsmRNA vaccine pioneers win medicine Nobel prize
Katalin Karikó and Drew Weissman honoured for breakthroughs that enable the rapid development of new vaccines, including several of those used against Covid-19
-
FeatureThe drug developers fighting the antibiotic resistance problem
Andy Extance talks to the researchers innovating across different drug classes in the hunt to develop new treatments
-
OpinionSurviving in the war of all against all
Cancers and bacteria develop resistance to drugs in remarkably similar ways
-
ResearchA force against fungi
With antifungal resistance on the rise, Leah Cowen’s lab wants to identify molecules that can capitalise on vulnerabilities in fungal pathogens
-
FeatureWho will pay for new antibiotics?
Governments around the world are starting to consider alternative funding models and incentives for antibiotics. Katrina Megget asks if it is enough
-
CareersSharing antimicrobial expertise with Parliament
Emily Stevenson is one of two interns working alongside Green Party peer, Baroness Natalie Bennett
-
BusinessHow can we maintain the effectiveness of existing antimicrobials?
Reducing environmental pollution and tackling quality issues to stave off resistance
-
-
-
FeatureCharting the rise in antimicrobial resistance
We look at the data behind antibiotic drug discovery and development, bacterial resistance and the financial problems with the current business model
-
ResearchMapping antibiotic’s binding of its target points to way to give drugs the killer edge
Technique that creates a comprehensive catalogue of mutations in antibiotic’s target reveals how drugs might be improved
-
ResearchSynthetic peptide mimics can act as antivirals
Peptoids disrupt enveloped viruses’ lipid membranes as well as targeting fungi and bacteria
-
ResearchRevived Neanderthal and Denisovan peptides show antibiotic activity
Molecular-scale ‘Jurassic Park’ process could uncover new medicines
-
OpinionCould cheap CRO rates threaten to destabilise biotech?
Pharmaceutical pipelines are heavily dependent on contract research organisations; we can’t afford for them to fail
-
ResearchClick chemistry offers new, efficient process to produce unique cancer-fighting antibodies
Chemical approach is fast and flexible and could be an alternative o using protein engineering
-
BusinessRevolutionising RSV prevention
New vaccines and a long-acting antibody aim to protect older adults and babies from respiratory syncytial virus